Results show that CD19-CAR T cells expressing the PD1:CD28 coreceptor had superior T-cell proliferation, cytokine production, and killing of PD-L1+ B-cell lymphoma cells in vitro and in vivo compared with the prototype CD19-CAR T cells. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.